viewCytoDyn Inc.

CytoDyn's triple-negative breast cancer drug leronlimab given to first patient in clinical trial

Results of the trial will determine whether the company will seek Breakthrough Therapy Designation for the treatment

Leronlimab works as an inhibitor of CCR5, a protein that plays a role in tumor invasion and metastasis

CytoDyn Inc (OTCMKTS:CYDY) said its metastatic triple-negative breast cancer treatment, leronlimab, has been given to the first patient of a new Phase 1b/2 clinical trial.

The results of the trial will determine the company’s regulatory fate, particularly whether it will seek Breakthrough Therapy Designation and accelerated approval with the US Food and Drug Administration, CytoDyn said in a statement on Saturday.

Leronlimab was previously granted Fast Track designation for mTNBC based on its metastatic tumor reduction rate of more than 98% in mice and for part of a combination therapy in patients with HIV.

In the now underway clinical trial, circulating tumor cells will be evaluated in each patient every three weeks.

READ: CytoDyn wins FDA approval for Phase 2 Study of leronlimab and Regorafenib as combo therapy

“Today marks a crucial milestone in our company’s history, launching CytoDyn into clinical development in the oncology space,” CEO Nader Pourhassan said in a statement. “We are optimistic about the potential of leronlimab to provide a new therapeutic option for the roughly 37,000 women that are diagnosed with triple-negative breast cancer each year in the United States.”

Leronlimab has already completed nine clinical trials and been given to 800 patients in HIV treatment programs, Pourhassan said, without a single drug-related serious adverse event.

The drug itself works as an inhibitor of CCR5, a protein that plays a role in tumor invasion and metastasis. Blocking CCR5 has been shown to reduce tumor metastases in laboratory and animal models of aggressive breast and prostate cancer.

Shares of CytoDyn surged 12% on Monday to $0.38.

—Updated to include closing price—

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: CytoDyn Inc.

Price: 1.085 USD

Market: OTCQB
Market Cap: $467.37 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...



Full interview: CytoDyn reveals more promising results from its clinical...

CytoDyn Inc (OTCMKTS:CYDY) CEO Nader Pourhassan tells Proactive the late-stage biotechnology company has revealed additional “promising results” from its clinical trials evaluating its lead drug leronlimab for the treatment of metastatic triple-negative breast cancer and metastatic breast...

3 days, 7 hours ago

2 min read